Clinical symptoms alone are not enough to predict the risk of chronic gastrointestinal ischaemia (CGI), a recent study has found. This suggests that radiologic evaluation of the mesenteric arteries is critical.
Female patients taking long-term proton pump inhibitors (PPIs) have threefold odds of tolerating half of their prior dose, suggesting that the female gender is associated with an increased probability for successful step-down, according to a recent study.
Elevated serum concentrations of C-reactive protein (CRP) during clinical remission are associated with hospitalization and associated intestinal resection in Crohn’s disease (CD) patients, a new study shows.
Tests for serum tissue transglutaminase (tTG) and endomysial antibodies (EMA) demonstrate low sensitivity for identifying persistent villous atrophy in patients with biopsy-confirmed coeliac disease undergoing follow-up biopsy on a gluten-free diet (GFD), according to a meta-analysis.
The vonoprazan-based triple therapy is superior to proton pump inhibitor-based triple therapy in terms of Helicobacter pylori eradication, although the two regimens show comparable tolerability and incidence of adverse events, according to a review and meta-analysis.
Patients with inflammatory bowel disease (IBD) who are treated with corticosteroids, immunosuppressants and biologics have a low risk of pneumonia caused by Pneumocystis jirovecii (PJP), a population-based cohort study has shown. This suggests that routine administration of PJP prophylaxis in this population may not be warranted.
There is a low incidence of misclassification of major organic disease in patients with irritable bowel syndrome (IBS), and the only significant risk factor for this misclassification is the increased symptom severity, a recent study has found.
Endoscopic dilation appears to be effective in the management of eosinophilic oesophagitis (EoE) in both children and adults, resulting in improvement in majority of patients with very low rates of major complications, according to a review and meta-analysis.
Saccharomyces boulardii has favourable safety and efficacy in the treatment of children aged 3 months to 5 years with acute rotavirus diarrhoea, based on a double-blind, randomised controlled trial from a developing country.
Celecoxib is preferred over naproxen when added to proton-pump inhibitor (PPI) for preventing recurrent upper gastrointestinal (GI) bleeding in patients at high risk of both GI and cardiovascular (CV) events, who require concomitant aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), according to the CONCERN* study.